Drew McCartney, Operating Committee Member of BelHealth, Joins Skila as Chief Executive Officer
Skila, a leading provider of fully managed Software-as-a-Service product launch management and key opinion leader management solutions to pharmaceutical and medical device companies, is pleased to announce the appointment of Drew McCartney as CEO.
MORRIS PLAINS, NJ, August 25, 2011
Skila, a leading provider of fully managed Software-as-a-Service (SaaS) product launch management and key opinion leader (KOL) management solutions to pharmaceutical and medical device companies, is pleased to announce the appointment of Drew McCartney as Chief Executive Officer.Harold Blue, Managing Partner of BelHealth Investment Partners L.P. ("BelHealth"), and Chairman of the Board of Skila, said "I am pleased and excited to have Drew lead our team at Skila and help drive our ambitious plans via organic growth and acquisitions to establish Skila as the leader in product lifecycle management and key opinion leader (KOL) management solutions throughout the life science industry."
Mr. McCartney has served in a variety of executive roles, including as CEO, for companies in the medical devices, services and informatics industry. Mr. McCartney started his career with American Hospital Supply and was VP of Global Marketing with Baxter Biotech. Mr. McCartney developed and executed the global strategic marketing direction for Baxter's $250 million blood systems unit, through which the company achieved significant sales growth, new product introductions and licensing relationships with partners worldwide.
More recently, Mr. McCartney served as the Executive-In-Residence at DW Healthcare Partners, a healthcare focused private equity fund. Prior to that, Drew was CEO of First Circle Medical and raised substantial capital from a combination of Boston Scientific Corporation, Tyco International and private equity and established commercial operations in Europe and China. Mr. McCartney also led a private equity-backed catheter stabilization company through a critical restructuring while developing and commercializing a number of technologies overseas and domestically.
Previously, Mr. McCartney was with the Battelle Memorial Institute and led their expansion into new healthcare markets in drug delivery and clinical informatics. Mr. McCartney holds a bachelor's degree in Government from the University of Virginia.
Simon Mason, the President and Chief Operating Officer of Skila, said "Drew is an excellent choice as leader for Skila as the company enters a period of significant expansion. His strong management experience and in-depth understanding of our industry will help continue to drive growth at Skila. I am looking forward to working closely with Drew."
Commenting on his appointment as CEO of Skila, Mr. McCartney said "I am truly excited about this opportunity. Skila has a unique business model and strategy, which focuses on helping its customers drive sales, maintain compliance and achieve their business goals. Having run an array of health care technology growth platforms, I'll bring a sense of the client's perspective that will be additive to the successes that Skila has achieved working with the world's leading pharmaceutical companies. Coming from prior private equity sponsored assignments, I can readily discern where M&A opportunities are abundant to extend and scale Skila's suite of services for its life sciences partners. I am looking forward to taking the company to the next level."
About Skila
Skila, a BelHealth company, is a global technology and services company specializing in fully managed Software-as-a-Service (SaaS) product launch lifecycle management and engagement / relationship management solutions for the healthcare industry. Skila's solutions address the broad needs of global marketing, medical, market access, executive and alliance management teams that include a unique methodology, robust technology and key continuous services for effectively managing global product launches, key opinion leader relationships, market access / managed care, business performance, competitive intelligence, and key partnerships and alliances.
Having developed strong relationships with a broad number of global Pharmaceutical companies, Skila's solutions have been deployed in 61 countries, supporting numerous global brands and more than 10 million user interactions. Skila's long-standing commitment and understanding of customers' needs has resulted in the exponential growth and adoption of our methodology, technology and continuous services as the business platform of choice for many of our clients.
About BelHealth Investment Partners
BelHealth Investment Partners L.P. ("BelHealth") is a private equity buyout fund focused exclusively on the small-cap healthcare industry. BelHealth acquires majority positions in healthcare companies that the BelHealth Team believes are undervalued or undermanaged and would benefit from the vast entrepreneurial and operating experience that BelHealth can deliver. Applying an active, hands-on approach to governance, BelHealth utilizes its experience to drive revenue and profit growth and achieve superior returns for its investors. For more information about BelHealth, please visit: http://www.BelHealth.com.